Other Products → LIPOLYSIS
MOUNJARO
Tirzepatide (2.5mg / 5mg / 7.5mg / 10mg)
MOUNJARO® is a once-weekly prescription injection containing tirzepatide, a dual GIP and GLP-1 receptor agonist developed by Eli Lilly for type 2 diabetes and approved indications.
Categories
+
Effects
+
Helps improve glycemic control by enhancing insulin secretion and reducing glucagon when glucose is elevated. It also regulates appetite and caloric intake.
SPEC
+
4 Pens
Content
+
Active Ingredient: Tirzepatide
Available Strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg / 0.5 mL currently supplied in Korea
Once-weekly subcutaneous injection
Single-dose pre-filled pen
4 pens per box
Price
+
Pricing may vary depending on the destination country, order quantity, and business requirements. Our sales team is ready to assist you with current pricing and availability. Feel free to contact us anytime.
